Dopamine D₂ Antagonists Impact Nicotine Reward Processing in Schizophrenia


Patients with schizophrenia who are prescribed potent dopamine D₂ receptor antagonists often increase smoking and experience difficulty quitting. Possibly, this is due to a mechanism of these medications to reduce the reward-enhancing effect of nicotine, according to a study published in Schizophrenia Bulletin .


Abilify has a very addictive quality to it, so I’m not too surprised